A federal court rules in favor of POM Wonderful July 22 in a lawsuit alleging false advertising and misleading marketing against competitor Purely Juice. The U.S. District Court for the Central California District ruling ordered Newport Beach, Calif.-based Purely Juice to pay $1.5 million in damages. The court ruled an independent lab found Purely Juice's "100 percent Pomegranate" product was adulterated, and the company "would have lost most or all of its market share had they not misrepresented the content." In a release, Los Angeles-based POM Wonderful President Matt Tupper acknowledges juice suppliers are pressured to add "sugar, colorants and cheap filler juices" as pomegranate crops struggle to keep up with consumer demand for the juice. "We hope this ruling serves as a wake-up call for all pomegranate juice producers to ensure their labels communicate clearly the origin and actual ingredients of their products," he adds. Studies have shown polyphenols in pomegranate juice to be beneficial for heart, prostate and erectile health, POM Wonderful says...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.
Joint procurement, if used by member states to respond to potential pricing and access challenges caused by a US most favored nations pricing policy, would cause more uncertainty for pharmaceutical companies, warn industry representatives.
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
